IMD business school for management and leadership courses

Generative AI is a key enabler for AstraZeneca’s drive to integrate AI capabilities, supporting everything from molecule design and synthesis prediction to automated clinical protocol drafting and real-world evidence analysis. These tools help optimize trial design, improve dose selection, and identify effective drug combinations, particularly in oncology. AstraZeneca also applies AI to analyze genomic data and imaging biomarkers, like PD-L1 in cancer tissues, enhancing precision medicine efforts. 

In October 2024, two of the organization’s smart factories, based in Wuxi, China, and Södertälje, Sweden, were awarded World Economic Forum (WEF) Global Lighthouse Network status. These sites represent pioneering practices in the use of AI and big data analytics. In January 2025, Rene Haas, CEO of semiconductor and software design company Arm, joined the AstraZeneca board. 

To ensure responsible adoption, AstraZeneca has established ethical AI principles aligned with its Code of Ethics and launched a company-wide upskilling program, including a generative AI accreditation pathway.